https://www.selleckchem.com/products/cc-115.html
On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT0369330 evaluates the safety and tolerability of durvalumab after sequential CRT (sCRT). Patients with stage III, unresectable NSCLC and no progression after platinum-based sCRT were enrolled to receiv
Like
Comment
Share
